A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
Primary Objective
To determine the RP2D and schedule of TL-895 in each cohort. The SRC will determine the RP2D and schedule for Cohorts 1, 2 and 3 based on safety and tolerability data obtained from each arm of that cohort.
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Brandon Mcmahon, MD
Study ID
Protocol Number: 20-3032
More information available at ClinicalTrials.gov: NCT04655118
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers